University of Rome Tor Vergata

IAMA Therapeutics Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, March 31, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Other Health, Drug development, Therapy, Lists of diseases, University of Rome Tor Vergata, Neuroscience, Disability in Canada, Behavioural sciences, United States Air Force Scientific Advisory Board, Autism, American Academy of Child and Adolescent Psychiatry, Psychiatry, IAMA, Computational chemistry, Neurodevelopmental disorder, Developmental Medicine & Child Neurology, CA, Epilepsy, Drug discovery, SAB, Yale University, Stanford University, University, Neurology, Pharmaceutical industry, Residential care, Child, Chemistry

IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, announced today the formation of a Scientific Advisory Board (SAB) consisting of world-renowned experts in computational chemistry, protein drug design, and neurodevelopmental disorders.

Key Points: 
  • IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, announced today the formation of a Scientific Advisory Board (SAB) consisting of world-renowned experts in computational chemistry, protein drug design, and neurodevelopmental disorders.
  • "These thought leaders bring deep scientific expertise in drug discovery and extensive clinical experience in drug development.
  • The founding members of the IAMA Therapeutics' SAB are:
    William L. Jorgensen - Sterling Professor of Chemistry at Yale University (New Haven, CT, USA).
  • More detailed biographies of the Scientific Advisory Board can be found online at:
    IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a difference in the lives of children suffering from brain disorders.

Catalent Announces Plan for Alessandro Maselli to Become New CEO Effective July 1, 2022

Retrieved on: 
Wednesday, January 5, 2022
Medical Supplies, Health, Medical Devices, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, Food industry, COVID-19, Information, University, Maselli, United Kingdom, ABB, University of Rome Tor Vergata, Drug Quality and Security Act, Acquisition, Growth, Failure, SGS, Patient, NYSE, CTLT, Goal, Securities Exchange Act of 1934, Phrase, Health, Board, S&P, Technology, Securities Act of 1933, Board of directors, Multimedia, Industry, Alstom, Excipient, Leadership, Management, Pharmaceutical industry, Catalent

I am confident that Alessandros leadership will enable Catalent to continue its record of strong performance and growth.

Key Points: 
  • I am confident that Alessandros leadership will enable Catalent to continue its record of strong performance and growth.
  • I am deeply honored to have the opportunity to succeed John as Catalents Chief Executive Officer, said Alessandro Maselli, President and Chief Operating Officer.
  • Alessandro Maselli has more than 11 years of experience at Catalent.
  • He joined Catalent in 2010 as Director of Operations at Catalents pharmaceutical, nutritional, and cosmetics plant in Aprilia, Italy.

AAGL to Offer an Extensive Lineup of Postgraduate and Continuing Medical Education Courses for the 50th Annual Global Congress on Minimally Invasive Gynecologic Surgery

Retrieved on: 
Friday, October 15, 2021
Linda, Mentorship, Division, AAGL, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Scientific programming language, University of Texas at Austin, Hysteroscopy, Obstetrics, Sofie (surgical robot), University, Research, Travel, University of Naples Federico II, Pelvic pain, Assistant professor, Associate, Uterine fibroid, Hysterectomy, Department, Infertility, Woman, CME, Education, Radiology, Uterine artery embolization, PG, Fibroid, University of Rome Tor Vergata, Female, Culture, Mayo Clinic, Pathology, Reproductive surgery, Congress, Rock, Court of general sessions, Anorexia nervosa (differential diagnoses), Surgeon, Session, Radiofrequency ablation, Curriculum, Safety, Medicine, Medical device

The Scientific Program at AAGL annual meetings are always meticulously developed and are renowned for offering the best in MIGS education.

Key Points: 
  • The Scientific Program at AAGL annual meetings are always meticulously developed and are renowned for offering the best in MIGS education.
  • This year's curriculum will consist of PG Courses, Hands-on Surgical Labs, Plenary Sessions, Panels, Debates and Open Communication breakout sessions.
  • Premiering this year, AAGL is excited to introduce AAGL Talks, 15-minute TED-like presentations prior to the General Sessions, that will also provide CME credits.
  • AAGL is a professional medical association of laparoscopic surgeons and is the global leader in minimally invasive gynecologic surgery.

First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Retrieved on: 
Thursday, October 14, 2021
World Health Organization, Ulcerative colitis, GI, FDA, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Budesonide, University, Colon, Acquisition, Fats, Needle, Pancolitis, Cramp, Bleeding, Inflammatory Bowel Diseases, EPI, WHO, University of Rome Tor Vergata, Clinical trial, Patient, Life, Food, Company, CEO, World, UP, Security (finance), Population, IBD, Enema, FW, NASDAQ, Niclosamide, U.S. Securities and Exchange Commission, BOCA, Steroid, First wave, Constipation, Nutrient, Digestion, Weight loss, Rectum, Abdominal pain, Cystic fibrosis, Diarrhea, Inflammation, Fatigue, Exocrine pancreatic insufficiency, Safety, UPS, Pharmaceutical industry

The trial formally launches the expansion of the companys clinical development program for niclosamide into indications for inflammatory bowel diseases.

Key Points: 
  • The trial formally launches the expansion of the companys clinical development program for niclosamide into indications for inflammatory bowel diseases.
  • Patient screening is underway at clinical trial sites in Italy and will start soon in Austria and Germany.
  • First Wave BioPharma is also planning a separate clinical trial to investigate an oral formulation of niclosamide as a potential treatment for pancolitis.
  • FW-UP is a niclosamide-based, small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS).

Enterprise Predictive SaaS Company KuantSol Selects Advisory Board

Retrieved on: 
Thursday, September 30, 2021
Data science, Compliance, Behavior, Time series, AI, Head, University of Rome Tor Vergata, CEO, University, Growth, Silicon, Leadership, PALO, Government, Science and technology in Asia, Management, Risk management, Medical device

PALO ALTO, Calif., Sept. 30, 2021 /PRNewswire-PRWeb/ --Quantitative Predictive SaaS firm KuantSol is excited to announce strategic advisory board.

Key Points: 
  • PALO ALTO, Calif., Sept. 30, 2021 /PRNewswire-PRWeb/ --Quantitative Predictive SaaS firm KuantSol is excited to announce strategic advisory board.
  • KuantSol has chosen the following leaders for its advisory board:
    Dr. Paul Russo, CEO of Kyto Technologies and a Silicon Valley startup and tech expert.
  • The new advisory board will provide guidance to KauntSol and help strengthen its relationships with customers to drive sustained growth and global expansion.
  • Through these products, KuantSol provides help to solve many challenges in TS/ML model development.

Green Hygienics Holdings Inc. (GRYN) Recruits Former Johnson & Johnson Head of Regulatory & Medical Affairs, Italy, as New Chief Scientific Officer

Retrieved on: 
Thursday, August 19, 2021
Company, OTCQB, University, George Fox University, Twitter, Growth, Instagram, Quality, Hygiene, Traditional Chinese medicine, GLOBE, Medical Affairs Bureau, University of Rome Tor Vergata, CPG, Cosmetics, Health, Chemical industry, Pfizer, Pharmacovigilance, SAN, LinkedIn, FDA, Diversified Specialty Institute Holdings, Inc., Medical device, Medicine

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Green Hygienics Holdings Inc. (OTCQB: GRYN) ("Green Hygienics" or the "Company") has appointed Dr. Francesca Serraino Fiory as the Companys new Chief Scientific Officer.

Key Points: 
  • SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Green Hygienics Holdings Inc. (OTCQB: GRYN) ("Green Hygienics" or the "Company") has appointed Dr. Francesca Serraino Fiory as the Companys new Chief Scientific Officer.
  • She will also lead collaborative partnerships with research centers and academic institutions and drive sustainable growth by guiding the Company across the global regulatory landscape.
  • Starting in Regulatory and Medical Affairs at Pfizer, she then took on the role of head of Regulatory and Medical Affairs at Johnson & Johnson Consumer Health Care, Italy.
  • For further information about Green Hygienics Holdings Inc., please visit the Companys website at: http://www.greenhygienics.com/
    Follow us on Facebook, Twitter , Instagram and Linkedin.

Green Hygienics Holdings Inc. (GRYN) Recruits Former Johnson & Johnson Head of Regulatory & Medical Affairs, Italy, as New Chief Scientific Officer

Retrieved on: 
Thursday, August 19, 2021
Company, OTCQB, University, George Fox University, Growth, Quality, Hygiene, Traditional Chinese medicine, GLOBE, Medical Affairs Bureau, University of Rome Tor Vergata, CPG, Cosmetics, Health, Chemical industry, Pfizer, Pharmacovigilance, SAN, FDA, Diversified Specialty Institute Holdings, Inc., Medical device, Medicine

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Green Hygienics Holdings Inc. (OTCQB: GRYN) ("Green Hygienics" or the "Company") has appointed Dr. Francesca Serraino Fiory as the Companys new Chief Scientific Officer.

Key Points: 
  • SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Green Hygienics Holdings Inc. (OTCQB: GRYN) ("Green Hygienics" or the "Company") has appointed Dr. Francesca Serraino Fiory as the Companys new Chief Scientific Officer.
  • She will also lead collaborative partnerships with research centers and academic institutions and drive sustainable growth by guiding the Company across the global regulatory landscape.
  • Starting in Regulatory and Medical Affairs at Pfizer, she then took on the role of head of Regulatory and Medical Affairs at Johnson & Johnson Consumer Health Care, Italy.
  • For further information about Green Hygienics Holdings Inc., please visit the Companys website at: http://www.greenhygienics.com/